Empowering patients for biomarker-informed care: digital education to bridge HER2-low knowledge gaps in metastatic breast cancer.

ABSTRACT:

Background

The emergence of trastuzumab deruxtecan has led to significant improvement in clinical outcomes for patients with HER2-low metastatic breast cancer, which accounts for approximately half (45%-55%) of breast cancer diagnoses. However, little is known about patients' awareness of diagnostic testing requirements and treatment implications associated with HER2-low status. This study aims to better understand patients' knowledge of HER2-low.

Methods

This cross-sectional survey was completed virtually on the Outcomes4Me mobile app, a direct-to-patient digital application that empowers patients to take a proactive approach to their care. Eligible patients included those with Stage IV breast cancer living in the United States. Participants were surveyed on their awareness

SUBMITTER: Ko HC 

PROVIDER: S-EPMC12738299 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature